KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) Other Operating Expenses (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Other Operating Expenses for 16 consecutive years, with $435.7 million as the latest value for Q4 2025.

  • Quarterly Other Operating Expenses rose 628.44% to $435.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $639.0 million through Dec 2025, up 177.27% year-over-year, with the annual reading at $639.0 million for FY2025, 177.27% up from the prior year.
  • Other Operating Expenses for Q4 2025 was $435.7 million at Halozyme Therapeutics, up from $73.0 million in the prior quarter.
  • The five-year high for Other Operating Expenses was $435.7 million in Q4 2025, with the low at $15.9 million in Q1 2022.
  • Average Other Operating Expenses over 5 years is $70.0 million, with a median of $58.6 million recorded in 2024.
  • The sharpest move saw Other Operating Expenses decreased 17.83% in 2021, then skyrocketed 628.44% in 2025.
  • Over 5 years, Other Operating Expenses stood at $21.6 million in 2021, then skyrocketed by 116.2% to $46.7 million in 2022, then surged by 50.11% to $70.1 million in 2023, then fell by 14.62% to $59.8 million in 2024, then surged by 628.44% to $435.7 million in 2025.
  • According to Business Quant data, Other Operating Expenses over the past three periods came in at $435.7 million, $73.0 million, and $64.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.